ScreenerHero

ORGOOrganogenesis Holdings, Inc. Class A

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · organogenesis.com
1.800USD-5.76%Mkt Cap: 231.61M $P/E: —

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced w…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.19BUSDP/E 23.7
TAK
Takeda Pharmaceutical Co. Ltd.
$58.06BUSD
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.98BUSDP/E 20.4
TEVA
Teva Pharmaceutical Industries Limited
$43.51BUSDP/E 62.2
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
ZTS
Zoetis Inc.
$32.12BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.01BUSDP/E 18.4
VTRS
Viatris, Inc.
$18.75BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.34BUSDP/E 117.3
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
NBIX
Neurocrine Biosciences, Inc.
$15.51BUSDP/E 22.3
ELAN
Elanco Animal Health Incorporat
$11.98BUSD
RDY
Dr. Reddy's Laboratories Ltd
$10.15BUSDP/E 29.7
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
ALKS
Alkermes plc
$8.11BUSDP/E 127.2
HIMS
Hims & Hers Health, Inc.
$7.88BUSD
LNTH
Lantheus Holdings Inc
$6.53BUSDP/E 23.9
AMRX
Amneal Pharmaceuticals, Inc. Class A
$6.24BUSDP/E 37.3
LQDA
Liquidia Corporation
$6.14BUSDP/E 49.0
KNSA
Kiniksa Pharmaceuticals, Ltd.
$6.08BUSDP/E 79.8

Key Statistics

Company
Market Cap231.61M $
Enterprise Value397.48M $
Revenue (TTM)457.45M $
Gross Profit425.51M $
Net Income (TTM)37.03M $
Revenue/Share3.586 USD
Last Price1.800 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees854
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINUS68621F1021
Valuation
P/E (Trailing)—
P/E (Forward)-5.94
PEG—
EV/EBITDA-40.97
EV/Revenue0.87
P/S0.52
P/B1.60
EPS (TTM)-0.76
EPS (Forward)-0.31
52W Range
1.5405% of range7.077
52W High7.077 USD
52W Low1.540 USD
Profitability
Gross Margin75.57%
Oper. Margin-119.25%
EBITDA Margin-2.12%
Profit Margin6.58%
ROE8.53%
ROA6.19%
Growth
Revenue Growth-56.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-10.31M $
CapEx (TTM)14.15M $
FCF Margin6.22%
FCF Yield12.28%
Net Debt20.85M $
Net Debt/EBITDA-2.15
Balance Sheet
Debt/Equity0.19
Current Ratio3.52
Quick Ratio2.58
Book Value/Sh1.152 USD
Cash/Share0.3580 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating3.0 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)2.000 USD
Upside (mean)+11.1%
Target Range2.000 USD – 2.000 USD
# Analysts1
Ownership
Shares Out.128.67M
Float61.06M
Insiders47.46%
Institutions51.82%
Short Interest
Short Ratio18.9d
Short % Float16.28%
Short % Out.10.35%
Shares Short13.31M
Short (prev mo.)13.80M
Technical
SMA 502.321 (-22.4%)
SMA 2003.300 (-45.5%)
Beta1.32
S&P 52W Chg18.16%
Avg Vol (30d)832.75K
Avg Vol (10d)1.19M
Technical Indicators
RSI (14)34.6
MACD-0.1814
MACD Signal-0.1428
MACD Hist.-0.0386
BB Upper2.791 USD
BB Middle2.156 USD
BB Lower1.522 USD
BB Width58.86%
ATR (14)0.1631 USD
Vol Ratio (20d)0.60x